L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Open Access
- 25 November 2024
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 78, 102952
Abstract
No abstract availableKeywords
Funding Information
- Government of Japan Ministry of Health Labour and Welfare (JPMH23FC1010)
- Osaka University
- Japan Agency for Medical Research and Development
This publication has 37 references indexed in Scilit:
- FARS‐ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important ChangeMovement Disorders, 2024
- Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders researchHeliyon, 2024
- Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onsetAnnals of Clinical and Translational Neurology, 2023
- Consensus Recommendations for Clinical Outcome Assessments and Registry Development in Ataxias: Ataxia Global Initiative (AGI) Working Group Expert GuidanceThe Cerebellum, 2023
- Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neuronsMolecular Therapy Nucleic Acids, 2021
- Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar AtaxiasNeurotherapeutics, 2019
- Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort studyThe Lancet Neurology, 2015
- Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyondThe Lancet Neurology, 2010
- Polyglutamine neurodegeneration: protein misfolding revisitedTrends in Neurosciences, 2008
- Cross-cultural validation of the Beck Depression Inventory-II in JapanPsychiatry Research, 2002